Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
John Charles ThomasEVP, General Counsel | Krystal BiotechKRYS | Open-market sale10b5-1 plan | 06/25 | 06/26 | 1,000 sh | $347.27 | $347,270 | −100.0% |
Krystal BiotechKRYS | Open-market sale10b5-1 plan | 06/04 | 06/05 | 25,000 sh11 trades | $308.12avg. | $7,703,027.87 | −1.7% | |
Krystal BiotechKRYS | Open-market sale10b5-1 plan | 06/04 | 06/05 | 25,000 sh11 trades | $308.12avg. | $7,702,882.93 | −1.8% | |
John Charles ThomasEVP, General Counsel | Krystal BiotechKRYS | Open-market sale10b5-1 plan | 05/26 | 05/27 | 642 sh | $302.03 | $193,903.26 | −100.0% |
Krystal BiotechKRYS | Open-market sale10b5-1 plan | 03/04 | 03/06 | 25,000 sh10 trades | $263.17avg. | $6,579,175.27 | −1.7% | |
Krystal BiotechKRYS | Open-market sale10b5-1 plan | 03/04 | 03/06 | 25,000 sh10 trades | $263.21avg. | $6,580,267.7 | −1.8% | |
Romano KathrynChief Accounting Officer | Krystal BiotechKRYS | Open-market sale10b5-1 plan | 03/02 | 03/03 | 750 sh | $267.60 | $200,700 | −3.2% |
Krystal BiotechKRYS | Open-market sale10b5-1 plan | 02/27 | 03/03 | 11,803 sh2 trades | $275.59avg. | $3,252,844.91 | −13.9% | |
Krystal BiotechKRYS | Open-market sale10b5-1 plan | 02/24–02/26 | 02/26 | 60,161 sh20 trades | $268.44avg. | $16,149,459.41 | No record | |
Krystal BiotechKRYS | Open-market sale | 02/19 | 02/23 | 18,950 sh2 trades | $261.41avg. | $4,953,728.24 | −19.4% | |
Krystal BiotechKRYS | Open-market sale10b5-1 plan | 02/09 | 02/11 | 12,500 sh7 trades | $272.14avg. | $3,401,702.88 | −39.3% | |
Krystal BiotechKRYS | Open-market sale10b5-1 plan | 25/12/04 | 25/12/05 | 50,000 sh16 trades | $220.15avg. | $11,007,481.96 | No record | |
Krystal BiotechKRYS | Open-market sale10b5-1 plan | 25/12/04 | 25/12/05 | 50,000 sh16 trades | $220.15avg. | $11,007,368.1 | No record | |
Krystal BiotechKRYS | Open-market sale10b5-1 plan | 25/07/14–25/07/16 | 25/07/16 | 35,873 sh9 trades | $150.39avg. | $5,394,985.75 | No record | |
Krystal BiotechKRYS | Open-market sale10b5-1 plan | 25/07/14–25/07/16 | 25/07/16 | 35,873 sh9 trades | $150.39avg. | $5,394,985.75 | No record | |
Krystal BiotechKRYS | Open-market sale10b5-1 plan | 25/07/09–25/07/10 | 25/07/11 | 14,127 sh6 trades | $150.27avg. | $2,122,878.94 | No record | |
Krystal BiotechKRYS | Open-market sale10b5-1 plan | 25/07/09–25/07/10 | 25/07/11 | 14,127 sh6 trades | $150.27avg. | $2,122,878.94 | No record | |
Krystal BiotechKRYS | Open-market sale10b5-1 plan | 25/03/13 | 25/03/13 | 50,000 sh10 trades | $177.79avg. | $8,889,549.93 | No record | |
Krystal BiotechKRYS | Open-market sale10b5-1 plan | 25/03/13 | 25/03/13 | 50,000 sh10 trades | $177.79avg. | $8,889,549.93 | No record | |
Romano KathrynChief Accounting Officer | Krystal BiotechKRYS | Open-market sale10b5-1 plan | 25/02/27 | 25/02/28 | 750 sh | $175.22 | $131,415 | −5.6% |